Identifying tumor biomarkers associated with clinical behavior in breast cancer patients may allow higher accuracy in the selection of treatment. Different types of cells were determined in the primary tumors of stage I, II, and III of breast cancer patients, who were assigned to one of the two groups: (1) disease-free or (2) relapsed/progressed, at 5 years after primary treatment. We studied 32 tumor samples. CD4+ lymphocytes and CD44+CD24−/low cells (cancer stem cells) showed a significant association with clinical outcome at 5 years of primary treatment, while CD8+, Foxp3+, CD34+, and myeloid-derived suppressor cells did not show any association. Coincident with the results of individual analysis, we identified CD4+ cells and CD44+CD24−/...
Identification of the different elements intervening at the tumor microenvironment seems key to expl...
BACKGROUND: Prognostic and treatment-predictive biomarkers in primary breast cancer are routinely an...
International audienceThe rationale for therapeutic targeting of Vδ2+ γδ T cells in breast cancer is...
<p>Identifying tumor biomarkers associated with clinical behavior in breast cancer patients may allo...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Various markers are used to identify the unique sub-population of breast cancer cells wi...
The tumor stem cell theory could explain how patients with metastatic disease show clinical relapse ...
Background: Modern clinical trials indicate that during system treatment change of breast cancer ph...
Cancer immunotolerance may be reversed by checkpoint inhibitor immunotherapy; how-ever, only a subse...
Pertaining to the female population in the USA, breast cancer is the leading cancer in terms of annu...
We thank the patients for their participation in the study. We also thank John Pope for excellent ed...
PURPOSE: Evidence is lacking whether the number of breast tumor-initiating cells (BT-ICs) directly c...
The clinical management of HER2+ breast cancer, which comprises approximately 20% of all breast canc...
Background: Breast cancers show variations in the number and biological aggressiveness of cancer ste...
To explore whether the CD44+/CD24(-/low)/ABCG2(-) (ATP binding cassette superfamily G member 2) cell...
Identification of the different elements intervening at the tumor microenvironment seems key to expl...
BACKGROUND: Prognostic and treatment-predictive biomarkers in primary breast cancer are routinely an...
International audienceThe rationale for therapeutic targeting of Vδ2+ γδ T cells in breast cancer is...
<p>Identifying tumor biomarkers associated with clinical behavior in breast cancer patients may allo...
Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting i...
Background: Various markers are used to identify the unique sub-population of breast cancer cells wi...
The tumor stem cell theory could explain how patients with metastatic disease show clinical relapse ...
Background: Modern clinical trials indicate that during system treatment change of breast cancer ph...
Cancer immunotolerance may be reversed by checkpoint inhibitor immunotherapy; how-ever, only a subse...
Pertaining to the female population in the USA, breast cancer is the leading cancer in terms of annu...
We thank the patients for their participation in the study. We also thank John Pope for excellent ed...
PURPOSE: Evidence is lacking whether the number of breast tumor-initiating cells (BT-ICs) directly c...
The clinical management of HER2+ breast cancer, which comprises approximately 20% of all breast canc...
Background: Breast cancers show variations in the number and biological aggressiveness of cancer ste...
To explore whether the CD44+/CD24(-/low)/ABCG2(-) (ATP binding cassette superfamily G member 2) cell...
Identification of the different elements intervening at the tumor microenvironment seems key to expl...
BACKGROUND: Prognostic and treatment-predictive biomarkers in primary breast cancer are routinely an...
International audienceThe rationale for therapeutic targeting of Vδ2+ γδ T cells in breast cancer is...